Angiotensin II Type 1 Receptor Blockers
"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.
| Descriptor ID |
D047228
|
| MeSH Number(s) |
D27.505.519.162.500
|
| Concept/Terms |
Angiotensin II Type 1 Receptor Blockers- Angiotensin II Type 1 Receptor Blockers
- Angiotensin II Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Blockers
- Angiotensin 2 Type 1 Receptor Antagonists
- Type 1 Angiotensin Receptor Antagonists
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".
This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in this website by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 1 | 3 |
| 2005 | 1 | 1 | 2 |
| 2006 | 5 | 1 | 6 |
| 2007 | 1 | 2 | 3 |
| 2008 | 2 | 3 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 3 | 1 | 4 |
| 2011 | 1 | 0 | 1 |
| 2012 | 2 | 3 | 5 |
| 2013 | 2 | 3 | 5 |
| 2014 | 4 | 2 | 6 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles.
-
Biologically Regulated Marrow Stimulation by Blocking TGF-?1 With Losartan Oral Administration Results in Hyaline-like Cartilage Repair: A Rabbit Osteochondral Defect Model. Am J Sports Med. 2020 03; 48(4):974-984.
-
Predictors of Rapid Aortic Root Dilation and Referral for Aortic Surgery in Marfan Syndrome. Pediatr Cardiol. 2018 Oct; 39(7):1453-1461.
-
Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: the SOPHIA study. Pharmacogenomics. 2014 Sep; 15(13):1643-52.
-
National prescribing trends for heart failure medications in children. Congenit Heart Dis. 2015 Jan-Feb; 10(1):78-85.
-
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest. 2014 Mar; 124(3):1329-39.
-
Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int. 2013 Nov; 84(5):931-9.
-
Comparison of once-daily versus twice-daily dosing of valsartan in patients with chronic stable heart failure. Vasc Health Risk Manag. 2010 Aug 09; 6:449-55.
-
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct size. Cardiovasc Drugs Ther. 2010 Apr; 24(2):107-20.
-
ACE inhibitor and angiotensin II type 1 receptor antagonist therapies in elderly patients with diabetes mellitus: are they underutilized? Drugs Aging. 2010 Feb 01; 27(2):87-94.
-
Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation. Vasc Health Risk Manag. 2009; 5:783-91.